Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2020

25.11.2019 | Editorial

Building Fences: How A20 Protects the Intestinal Mucosa in Inflammatory Bowel Diseases

verfasst von: Deenaz Zaidi, Eytan Wine

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Excerpt

Inflammatory bowel diseases (IBD), including Crohn disease (CD) and ulcerative colitis (UC), are chronic diseases with no definite cure found to date. The etiology of IBD is complex, as many factors are associated with disease onset and/or progression, including environmental factors (e.g., geographical variation, smoking, antibiotics, diet, and microbes), genetics, and a dysfunctional gut barrier [1]. Multifactorial involvement renders it difficult to pinpoint a single causative agent and provide targeted treatment for IBD. As a result, current treatment paradigms focus on inducing remission and reducing the frequency of flares, mostly by suppressing the uncontrolled immune response; this of course introduces treatment risks, including infection and malignancy. …
Literatur
1.
Zurück zum Zitat Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology. 2019;157:647–659.CrossRef Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology. 2019;157:647–659.CrossRef
2.
Zurück zum Zitat Allen IC, Eden K, Nguyen V, Knight C, Sorrentino D. Noncanonical NF-κB signaling is elevated in inflammatory bowel disease patients and may be associated with therapeutic response. J Immunol. 2017;198(1 Supplement):197.5. Allen IC, Eden K, Nguyen V, Knight C, Sorrentino D. Noncanonical NF-κB signaling is elevated in inflammatory bowel disease patients and may be associated with therapeutic response. J Immunol. 2017;198(1 Supplement):197.5.
3.
Zurück zum Zitat Ślebioda TJ, Kmieć Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat Inflamm. 2014;2014:325129.CrossRef Ślebioda TJ, Kmieć Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat Inflamm. 2014;2014:325129.CrossRef
4.
Zurück zum Zitat Zaidi D, Wine E. Regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κβ) in inflammatory bowel diseases. Front Pediatr. 2018;10:317.CrossRef Zaidi D, Wine E. Regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κβ) in inflammatory bowel diseases. Front Pediatr. 2018;10:317.CrossRef
5.
Zurück zum Zitat Vereecke L, Sze M, Mc Guire C, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207:1513–1523.CrossRef Vereecke L, Sze M, Mc Guire C, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207:1513–1523.CrossRef
6.
Zurück zum Zitat Kolodziej LE, Lodolce JP, Chang JE, et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS One. 2011;6:e26352.CrossRef Kolodziej LE, Lodolce JP, Chang JE, et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS One. 2011;6:e26352.CrossRef
7.
Zurück zum Zitat Zaidi D, Huynh Q, Carroll M, et al. Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease. Clin Exp Gastroenterol. 2018;11:217–231.CrossRef Zaidi D, Huynh Q, Carroll M, et al. Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease. Clin Exp Gastroenterol. 2018;11:217–231.CrossRef
9.
Zurück zum Zitat Arsenescu R, Bruno MEC, Rogier EW, et al. Signature biomarkers in Crohn’s disease: toward a molecular classification. Mucosal Immunol. 2008;1:399–411.CrossRef Arsenescu R, Bruno MEC, Rogier EW, et al. Signature biomarkers in Crohn’s disease: toward a molecular classification. Mucosal Immunol. 2008;1:399–411.CrossRef
10.
Zurück zum Zitat Fernandes P, MacSharry J, Darby T, et al. Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn’s disease: a role for Tollip and peroxisome proliferator-activated receptor gamma? Clin Exp Immunol. 2016;183:358–368.CrossRef Fernandes P, MacSharry J, Darby T, et al. Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn’s disease: a role for Tollip and peroxisome proliferator-activated receptor gamma? Clin Exp Immunol. 2016;183:358–368.CrossRef
Metadaten
Titel
Building Fences: How A20 Protects the Intestinal Mucosa in Inflammatory Bowel Diseases
verfasst von
Deenaz Zaidi
Eytan Wine
Publikationsdatum
25.11.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05964-1

Weitere Artikel der Ausgabe 5/2020

Digestive Diseases and Sciences 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.